Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
featured
Published in Oncology

Journal Scan / Research · June 04, 2020

Improved Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors

JAMA Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Paul Hampel MD

JAMA Oncology
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-Up
JAMA Oncol 2020 May 29;[EPub Ahead of Print], H Joensuu, M Eriksson, K Sundby Hall, A Reichardt, B Hermes, J Schütte, S Cameron, P Hohenberger, PJ Jost, SE Al-Batran, LH Lindner, S Bauer, E Wardelmann, B Nilsson, R Kallio, P Jaakkola, J Junnila, T Alvegård, P Reichardt

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated